NICE has published a draft verdict on the use of Roche's Tarceva (erlotinib) and Eli Lilly's Alimta (pemetrexed) to treat patients with non-small cell lung cancer yesterday, concluding that there is no evidence the drug is more cost-effective than the older treatment docetaxel.
In a statement, NICE's chief executive, Andrew Dillon said: "Our initial assessment of the evidence shows that neither of these drugs represents a good use of scarce NHS resources."
"The available evidence on both erlotinib and pemetrexed shows they do not provide better overall survival or progression-free survival than the other commonly used but less expensive alternative," he added.
No comments:
Post a Comment